Weatherly Asset Management L. P. Sells 182 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Weatherly Asset Management L. P. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,357 shares of the company’s stock after selling 182 shares during the quarter. Weatherly Asset Management L. P.’s holdings in IDEXX Laboratories were worth $561,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares during the period. Retirement Wealth Solutions LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $31,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after buying an additional 60 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $37,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on IDXX shares. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Finally, Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Trading Up 1.1 %

Shares of IDXX stock opened at $464.91 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. The stock has a market cap of $38.07 billion, a P/E ratio of 43.57, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The stock has a 50 day simple moving average of $428.35 and a 200 day simple moving average of $453.32. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.